India’s Matrix To Hold Controlling Interest In Astrix Joint Venture
This article was originally published in PharmAsia News
U.S.-based Mylan Laboratories and its Indian arm, Matrix Laboratories, have agreed that Mylan will buy a half interest in Astrix Laboratories, a joint venture that makes anti-retroviral active pharmaceutical ingredients. Matrix and Aspen Pharmacare Holdings of South Africa formed Astrix as a joint venture, but decided last year that Matrix would buy out Aspen's 50 percent share. Instead, the plan now is to have Mylan, Matrix's parent, buy 49 percent of Aspen's shares through another Mylan subsidiary and Matrix's immediate parent, MP Laboratories of Mauritius. Matrix, already a 50 percent owner, is to buy the remaining 1 percent for control of Astrix. (Click here for more
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.